Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Takeda
ClinicalTrials.gov Identifier:
NCT00760344
First received: September 24, 2008
Last updated: May 18, 2012
Last verified: May 2012

September 24, 2008
May 18, 2012
March 2007
March 2008   (final data collection date for primary outcome measure)
Change from baseline in glycosylated hemoglobin [ Time Frame: Week 12 or Final Visit ] [ Designated as safety issue: No ]
Change from baseline in glycosylated hemoglobin [ Time Frame: Final Visit ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00760344 on ClinicalTrials.gov Archive Site
  • Change from baseline in glycosylated hemoglobin [ Time Frame: Weeks 4, 8 and 12 or Final Visit. ] [ Designated as safety issue: No ]
  • Change from baseline in fasting plasma glucose [ Time Frame: Weeks 1, 2, 4, 8, and 12 or Final Visit ] [ Designated as safety issue: No ]
  • Change from baseline in 1,5-Anhydroglucitol [ Time Frame: Weeks 2, 4, 8, and 12 or Final Visit. ] [ Designated as safety issue: No ]
  • Change from baseline in Proinsulin [ Time Frame: Weeks 4, 8, and 12 or Final Visit. ] [ Designated as safety issue: No ]
  • Change from baseline in Insulin [ Time Frame: Weeks 4, 8, and 12 or Final Visit. ] [ Designated as safety issue: No ]
  • Change from baseline in Proinsulin/insulin ratio [ Time Frame: Weeks 4, 8, and 12 or Final Visit. ] [ Designated as safety issue: No ]
  • Change from baseline in C-peptide [ Time Frame: Weeks 4, 8, and 12 or Final Visit. ] [ Designated as safety issue: No ]
  • Change from baseline in Homeostasis model assessment of insulin resistance. [ Time Frame: Weeks: 4, 8, and 12 or Final Visit. ] [ Designated as safety issue: No ]
  • Change from baseline in Homeostasis model assessment of beta-cell function. [ Time Frame: Weeks 4, 8, and 12 or Final Visit. ] [ Designated as safety issue: No ]
  • Incidence of marked hyperglycemia (fasting plasma glucose greater than or equal to 200 mg/dL [11.10 mmol/L]). [ Time Frame: Weeks 4, 8 and 12 or Final Visit. ] [ Designated as safety issue: No ]
  • Incidence of rescue. [ Time Frame: Weeks 1, 2, 4, 8, and 12 or Final Visit. ] [ Designated as safety issue: No ]
  • Clinical response endpoint incidence of glycosylated hemoglobin less than or equal to 6.5%. [ Time Frame: Week 12 or Final Visit ] [ Designated as safety issue: No ]
  • Clinical response endpoint incidence of glycosylated hemoglobin less than or equal to 7.0%. [ Time Frame: Week 12 or Final Visit ] [ Designated as safety issue: No ]
  • Change from baseline in Fasting lipids (triglycerides, total cholesterol, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol). [ Time Frame: Weeks 4, 8, and 12 or Final Visit. ] [ Designated as safety issue: No ]
  • Body weight. [ Time Frame: Weeks 4, 8, and 12 or Final Visit. ] [ Designated as safety issue: No ]
  • Change from baseline in glycosylated hemoglobin [ Time Frame: Weeks 4, 8 and 12. ] [ Designated as safety issue: No ]
  • Change from baseline in fasting plasma glucose [ Time Frame: At all Visits ] [ Designated as safety issue: No ]
  • Change from baseline in 1,5-Anhydroglucitol [ Time Frame: Weeks 2, 4, 8, and 12. ] [ Designated as safety issue: No ]
  • Change from baseline in Proinsulin [ Time Frame: Weeks 4, 8, and 12. ] [ Designated as safety issue: No ]
  • Change from baseline in Insulin [ Time Frame: Weeks 4, 8, and 12. ] [ Designated as safety issue: No ]
  • Change from baseline in Proinsulin/insulin ratio [ Time Frame: Weeks 4, 8, and 12. ] [ Designated as safety issue: No ]
  • Change from baseline in C-peptide [ Time Frame: Weeks 4, 8, and 12. ] [ Designated as safety issue: No ]
  • Change from baseline in Homeostasis model assessment of insulin resistance. [ Time Frame: Weeks: 4, 8, and 12. ] [ Designated as safety issue: No ]
  • Change from baseline in Homeostasis model assessment of beta-cell function. [ Time Frame: Weeks 4, 8, and 12. ] [ Designated as safety issue: No ]
  • Incidence of marked hyperglycemia (fasting plasma glucose greater than or equal to 200 mg/dL [11.10 mmol/L]). [ Time Frame: At all Visits ] [ Designated as safety issue: No ]
  • Incidence of rescue. [ Time Frame: At all Visits ] [ Designated as safety issue: No ]
  • Clinical response endpoint incidence of glycosylated hemoglobin less than or equal to 6.5%. [ Time Frame: At all Visits ] [ Designated as safety issue: No ]
  • Clinical response endpoint incidence of glycosylated hemoglobin less than or equal to 7.0%. [ Time Frame: At all Visits ] [ Designated as safety issue: No ]
  • Change from baseline in Fasting lipids (triglycerides, total cholesterol, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol). [ Time Frame: Weeks 4, 8, and 12. ] [ Designated as safety issue: No ]
  • Body weight. [ Time Frame: Weeks 4, 8, and 12. ] [ Designated as safety issue: No ]
  • Physical examination findings (including a clinical examination of skin and digits). [ Time Frame: At all Visits (and follow up visit at week 14). ] [ Designated as safety issue: No ]
  • Vital sign measurements (systolic and diastolic blood pressure, heart rate). [ Time Frame: At all Visits (and follow up visit at week 14). ] [ Designated as safety issue: No ]
  • Body temperature measurements. [ Time Frame: Screening Visit and Final Visit. ] [ Designated as safety issue: No ]
  • 12-lead electrocardiogram tracings intervals. [ Time Frame: Weeks 2, 8 and 12. ] [ Designated as safety issue: No ]
  • Incidence of adverse events. [ Time Frame: At all Visits (and follow up visit at week 14). ] [ Designated as safety issue: Yes ]
  • Incidence of hypoglycemia (blood glucose <60 mg/dL [<3.33 mmol/L] in the presence of symptoms, or blood glucose <50 mg/dL [<2.78 mmol/L] with or without symptoms). [ Time Frame: At all Visits. ] [ Designated as safety issue: No ]
  • Change from baseline in Clinical laboratory evaluations (hematology and serum chemistry). [ Time Frame: At all Visits. ] [ Designated as safety issue: Yes ]
  • Change from baseline in Clinical laboratory evaluations (urinalysis). [ Time Frame: Final Visit ] [ Designated as safety issue: Yes ]
  • Plasma concentrations of SYR-472 and percentage inhibition of dipeptidyl peptidase-4 activity. [ Time Frame: Weeks 4 and 8. ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate Treatment With SYR-472 in Subjects With Type 2 Diabetes

The purpose of this study is to determine the efficacy and safety of SYR-472, once daily (QD), in subjects with type 2 diabetes mellitus who have not achieved glycemic control with diet and exercise, or by taking metformin.

Type 2 diabetes mellitus is a complex metabolic disorder characterized by abnormal insulin secretion and glucose homeostasis, resulting from impaired pancreatic beta-cell function and insulin resistance in target tissues. The worldwide prevalence of type 2 diabetes mellitus is reaching epidemic proportions, and the total number of cases is expected to reach 221 million by 2010. The high incidence of the disease and its associated complications places a significant burden on healthcare systems.

The primary risk factor for the development of type 2 diabetes mellitus is obesity and its associated insulin resistance. Insulin resistance is characterized by an impaired response to the physiologic effects of insulin and leads to decreased cellular glucose uptake, increased hepatic gluconeogenesis, and a compensatory increase in insulin secretion that contributes to beta-cell exhaustion. Therefore in the insulin-resistant state, blood glucose and insulin levels are increased. The relationship between improved glycemic control in patients with type 2 diabetes mellitus and the delay or prevention of comorbidities has been reported in the Diabetes Control and Complications Trial and the United Kingdom Prospective Diabetes Study. Therefore, reduction of persistent hyperglycemia is the highest priority in treating this disease.

Diet and exercise are important and effective measures for maintaining glycemic control in individuals with insulin resistance, impaired glucose tolerance, and type 2 diabetes mellitus, particularly in the early stages of disease progression. In cases where diet and exercise alone fail to adequately maintain glycemic control, oral antidiabetic drugs are typically used. Combination oral therapy and eventually insulin are usually required to maintain lower blood glucose levels but can result in adverse effects including hypoglycemia and weight gain. Therefore, novel safe and effective antidiabetic therapies are needed.

Dipeptidyl peptidase-4 is a ubiquitous aminopeptidase that is widely expressed in many tissues; it is thought to be primarily responsible for the in vivo degradation of at least two gut-derived incretin hormones, namely glucagon-like peptide-1 and glucose-dependent insulinotropic peptide, which are both released in response to nutrient ingestion. Glucagon-like peptide-1 has been demonstrated to augment glucose-dependent insulin secretion; suppress glucagon release and hepatic gluconeogenesis; inhibit gastric emptying, and reduce appetite and food intake. Glucagon-like peptide-1 and glucose-dependent insulinotropic peptide also have been shown to promote insulin biosynthesis and stimulate beta cell proliferation and survival. Orally available inhibitors of dipeptidyl peptidase-4 activity have been developed that increase intact postprandial glucagon-like peptide-1 levels after oral administration.

SYR-472 is a selective inhibitor of dipeptidyl peptidase-4 in development to improve glycemic control in patients with type 2 diabetes mellitus. The aim of this study is to evaluate SYR-472 in subjects with type 2 diabetes mellitus who have not previously achieved adequate glycemic control with lifestyle modification (diet/exercise) or metformin antidiabetic monotherapy. Study participation is anticipated to be up to 20 weeks.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Diabetes Mellitus
  • Drug: SYR-472
    SYR-472 3.125 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
  • Drug: SYR-472
    SYR-472 12.5 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
  • Drug: SYR-472
    SYR-472 50 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
  • Drug: SYR-472
    SYR-472 100 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
  • Drug: Placebo
    SYR-472 placebo-matching tablets, orally, once daily with lifestyle modification and/or metformin therapy for up to 12 weeks.
  • Drug: Sitagliptin
    Sitagliptin 100 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
    Other Name: Januvia™
  • Experimental: SYR-472 3.125 mg QD
    (with lifestyle modification and/or metformin stable dose therapy)
    Intervention: Drug: SYR-472
  • Experimental: SYR-472 12.5 mg QD
    (with lifestyle modification and/or metformin stable dose therapy)
    Intervention: Drug: SYR-472
  • Experimental: SYR-472 50 mg QD
    (with lifestyle modification and/or metformin stable dose therapy)
    Intervention: Drug: SYR-472
  • Experimental: SYR-472 100 mg QD
    (with lifestyle modification and/or metformin stable dose therapy)
    Intervention: Drug: SYR-472
  • Placebo Comparator: Placebo QD
    (with lifestyle modification and/or metformin stable dose therapy)
    Intervention: Drug: Placebo
  • Active Comparator: Sitagliptin 100 mg QD
    (with lifestyle modification and/or metformin stable dose therapy)
    Intervention: Drug: Sitagliptin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
386
March 2008
March 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Had a historical diagnosis of type 2 diabetes mellitus.
  • Had undergone less than 7 days of any antidiabetic therapy except lifestyle modification (diet/exercise) within 8 weeks prior to Screening; or has received metformin monotherapy for at least 8 weeks prior to Screening and maintained a stable daily dose of metformin for at least 12 weeks prior to randomization.
  • If receiving metformin monotherapy at randomization must have been at least 75% compliant with his or her regimen during the Run in/Stabilization Period as determined by subject diary and investigator assessment.
  • Had received no treatment with antidiabetic agents other than metformin within the 8 weeks prior to Screening.
  • The subject has an glycosylated hemoglobin concentration between 7.0% and 10.0%, inclusive, at Screening and at the Week -1 Visit.
  • Had a body mass index between 23 and 45 kg/m2.
  • A C-peptide concentration is greater than or equal to 0.8 ng/mL (greater than or equal to 0.26 nmol/L).
  • A fasting plasma glucose concentration is less than 275 mg/dL (less than 15.27 mmol/L) at Screening and at the Week -1 Visit.
  • If the subject regularly uses other non-excluded medications, he or she must be on a stable dose for at least the 4 weeks prior to Screening.
  • The subject has a systolic blood pressure reading of less than 160 mm Hg and a diastolic pressure reading of less than 100 mm Hg.
  • The subject has a hemoglobin value greater than or equal to 12 g/dL (greater than or equal to 120 g/L) for men and greater than or equal to 10 g/dL (greater than or equal to 100 g/L) for women.
  • Had an alanine aminotransferase level is less than or equal to 3 times the upper limit of normal.
  • A male subject has a serum creatinine value of less than 1.5 mg/dL (less than 133 μmol/L); a female subject has a serum creatinine value of less than 1.4 mg/dL (less than 124 μmol/L).
  • Had a urine albumin/creatinine ratio of less than 1000 μg/mg at Screening.
  • Had a thyroid-stimulating hormone level less than or equal to the upper limit of the normal range and the subject is clinically euthyroid.
  • A female subject of childbearing potential who is sexually active must agree to use adequate contraception, and must be neither pregnant nor lactating from Screening and throughout the duration of the study.
  • Was able and willing to monitor his or her own blood glucose concentrations with a home glucose monitor.
  • Had no major illness or debility that in the investigator's opinion prohibits the subject from completing the study.

Exclusion Criteria:

  • Was being concurrently treated with antidiabetic therapy other than metformin and lifestyle intervention.
  • Had a history of cancer, other than squamous cell or basal cell carcinoma of the skin that has not been in full remission for at least 5 years prior to Screening.
  • Had a history of laser treatment for proliferative diabetic retinopathy within the 6 months prior to Screening.
  • Had a history of treated diabetic gastric paresis.
  • Had a New York Heart Association class III or IV heart failure regardless of therapy.
  • Had a history of coronary angioplasty, coronary stent placement or coronary bypass surgery, myocardial infarction, or stroke within the 6 months prior to Screening.
  • Had a history of hemoglobinopathy that may affect determination of glycosylated hemoglobin.
  • Had a history of infection with human immunodeficiency virus.
  • Had a history of a psychiatric disorder that in the investigator's opinion will affect the subject's ability to participate in the study.
  • Had a history of alcohol abuse (defined as regular or daily consumption of more than 4 alcoholic drinks per day) or substance abuse (defined as illicit drug use) within the 2 years prior to Screening.
  • Was required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:

    • Ingested or received systemically injected glucocorticoids within the 3 months prior to randomization.
    • Used prescription or over-the-counter weight-loss drugs within the 3 months prior to randomization.
    • Received any investigational drug within the 30 days prior to Screening or has received an investigational antidiabetic drug within the 3 months prior to Screening.
  • Had received previous treatment in an investigational study of SYR-472.
  • Had a known hypersensitivity to any compound related to SYR-472 or Sitagliptin.
Both
18 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Mexico
 
NCT00760344
01-06-TL-SYR-472-006, U1111-1129-7916
No
Takeda
Takeda
Not Provided
Study Director: VP Biological Sciences Takeda
Takeda
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP